Liquid chromatography-tandem mass spectrometry for therapeutic drug monitoring of immunosuppressants and creatinine from a single dried blood spot using the Capitainer® qDBS device

• Published in: Analytica chimica acta Vol. 1242; p. 340797
• Main Authors: Deprez, Sigrid, Van Uytfanghe, Katleen, Stove, Christophe P.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 15-02-2023
• Subjects: (Volumetric) dried blood spots; Capitainer® qDBS device; Chromatography, Liquid - methods; Creatinine; Cyclosporine; Dried Blood Spot Testing - methods; Drug Monitoring - methods; Everolimus; Humans; Immunosuppressants; Immunosuppressive Agents; Liquid chromatography-tandem mass spectrometry; Sirolimus; Tacrolimus; Tandem Mass Spectrometry - methods; Therapeutic drug monitoring; Therapeutic drug monitoring; Creatinine; Liquid chromatography-tandem mass spectrometry; Immunosuppressants; Capitainer® qDBS device; (Volumetric) dried blood spots
• ISSN: 0003-2670; 1873-4324
• DOI: 10.1016/j.aca.2023.340797

In recent years, a lot of attention has been given to a more patient-centric therapeutic drug monitoring (TDM) of immunosuppressant drugs (tacrolimus, sirolimus, everolimus and cyclosporin A) by the use of microsampling techniques. By adopting Dried Blood Spots (DBS) after a finger prick, instead of conventional venous blood draws, follow-up can (partially) be established from patients’ homes. Despite the many advantages of DBS, one of the major disadvantages associated with this technique is the well described hematocrit (hct) effect. In order to overcome the hct area bias, different strategies have been proposed, amongst which the use of dried blood sampling techniques based on the volumetric collection of blood.
The aim of this study was to evaluate the use of the Capitainer® qDBS (quantitative Dried Blood Spot) device for the combined TDM of four immunosuppressants and creatinine from a single qDBS. The set-up of an adequate sample preparation allowing both immunosuppressants and creatinine quantification was one of the key challenges in the method development due to device-specific interferences. Liquid chromatography tandem-mass spectrometry methods for the quantification of tacrolimus, sirolimus, everolimus, cyclosporin A and creatinine from qDBS (10 μL) were developed and validated based on international guidelines, also taking into account DBS-specific parameters. The methods proved to be accurate and reproducible, with absolute biases below 10% and within-run CVs (%) below 8% over a calibration range from 1 to 50 ng/mL for tacrolimus, sirolimus and everolimus, 20–1500 ng/mL for cyclosporin A, and 15–700 μmol/L for creatinine. Reproducible (CV < 15%) IS-compensated relative recovery values were obtained, showing no hematocrit-dependence (compared to a hct of 0.37), except for cyclosporin A at higher hct values. Application on venous blood left-over patient samples showed good agreement between the results of Capitainer® qDBS and whole blood with 98% (47/48), 93% (41/44), 89% (41/46), 88% (38/43) and 89% (116/131) of the samples lying within 20% of the whole blood result for tacrolimus, sirolimus, everolimus, cyclosporin A and plasma/serum for creatinine, respectively. For creatinine a blood/plasma ratio of 0.85 was found and used to convert qDBS results to plasma/serum results. As a next step, capillary finger prick samples will need to demonstrate the clinical applicability of the method in a real life setting.
[Display omitted]
•Validation of LC-MS/MS-based methods for quantification of immunosuppressants and creatinine using Capitainer® qDBS device.•Use of a single qDBS for both determinations.•Set-up of an adequate sample preparation was one of the key challenges due to device-specific interferences.•Application on venous qDBS patient samples and comparison with venous whole blood yielded a good agreement.